Halioseek® PD-L1/CD8 Toward an improved prediction of response to ICIs

in Non-Small Cell Lung Cancer

Why Halioseek® PD-L1/CD8?

Halioseek® PD-L1/CD8 is intended for the detection of PD-L1 protein and the concomitant detection of CD8 + cells in Non-Small Cell Lung cancer (NSCLC) tissue.

Halioseek® PD-L1/CD8, as a member of the Immunoscore® family assays, is a standardized
Immunohistochemistry (IHC)-based assay.

In addition, HalioDx provides image and data analysis services allowing standardized quantification of both PD-L1+ and CD8+ cell populations and the assessment of cells clustering as well as a proximity index. These measures aim to help identifying which NSCLC patients may best respond to anti-PD1 or anti-PD-L1 immunotherapies.

Halioseek® PD-L1/CD8 is available as a CE-IVD assay for PD-L1+ cells detection and as an RUO* solution in the Rest of The World through our comprehensive offer integrating HalioDx service laboratory.

 

* For Research Use Only. Not for use in diagnostic procedures.

Halioseek® PD-L1/CD8
Indication: NSCLC
Material: One FFPE slide
Assay: PD-L1+ & CD8+ cells detection by immunohistochemistry
Digital pathology: computation of CD8+ & PD-L1+ cell densities
Score & report: clustering of CD8+ & PD-L1+ cells
and CD8+ & PD-L1+ proximity index

Halioseek® PD-L1/CD8 solution consists in two parts:

  1. Halioseek® PD-L1/CD8 IHC kit includes ready-to-use anti-PD-L1 and anti-CD8 antibodies and controls for IHC dual-staining. The stained slide is directly readable by the pathologist to determine the percentage of PD-L1 positive tumor cells, evaluate the presence of PDL1+ immune cells and of CD8+ cells.
  2. Image analysis using Halioseek® Analyzer for complementary descriptive information:
  • Standardized computation of CD8+ and PD-L1+ cell densities on the same slide
  • PD-L1+ and CD8+ cells clustering
  • Proximity index between PD-L1+ and CD8+ cells

 

Clinical utility

Halioseek® PD-L1/CD8 is intended to help clinicians defining immunotherapy treatment strategy for patients with NSCLC.

Anti-PD-1/PD-L1 are now established treatments for advanced NSCLC patients; however, PD-L1 predictive value is not optimal. Association of PD-L1 + TC % with the assessment of tumor-infiltrating lymphocytes (TILs) via CD8+ T cells quantification and proximity measurement should improve the selection of patients likely to respond to Immune Checkpoint Inhibitors treatment.

See Halioseek® PD-L1/CD8 Digital Pathology Tool Performance (SITC 2017)

How to Order

Halioseek® PD-L1/CD8 workflow

Interested in ordering Halioseek® PD-L1/CD8 ? contact us

Scientific Data

Supportive data & reference publications PD-L1 & CD8 

Replay of the webinar on "Halioseek® PD-L1/CD8" beyond a simple PD-L1 testing. Performance and capacity to improve NSCLC patient stratification for Immune Checkpoint Inhibitors (ICI) treatments.
  • Poster presented at AACR2018Multi-centric PD-L1 and CD8 IHC assessment in NSCLC using Halioseek® CE-IVD assay
  • Poster presented at AACR 2017A new standardized CD8 and PD-L1 dual assay
  • Poster presented at SITC 2017 Halioseek® PD‐L1/CD8 assay is equivalent to other validated IVD assays and can be used by clinicians for therapeutic indications in NSCLC. It allows to quantify CD8 T‐cells infiltration on the same slide and provides additional digital pathology tools which could further improve patients selection for treatment with Immune Checkpoint Inhibitors (ICI). Halioseek® PD‐L1/CD8 could have a higher predictive performance than existing IVD tests and could fill a major gap in the management of ICI administration.

Selected publications

Contact us

Contact our team about Immunoscore® Colon

 
   

The information about you collected through this form is used by HalioDx to handle your request. Fields with an asterisk are mandatory. Otherwise, your request for information cannot be processed. Your data will be processed by HalioDx authorized services, and might be transmitted to external service providers processing your data on behalf of HalioDx. For more information on protection mechanisms implemented, please contact the data Protection Officer: privacy(at)haliodx(dot)com.
The information about you collected through this form will be kept for a period of 1 year from the last contact. At the end of this period, they will be erased. By subscribing to our newsletter, you accept to receive information on our news and events by email. You can unsubscribe any time by clicking on the unsubscribe link at the bottom of our newsletters, or by sending us an unsubscribe request at privacy(at)haliodx(dot)com.
You have the right to access, rectify, and to object to the processing of your personal data, and from the date the General Data Protection Regulation is applicable (25 May, 2018), the right to obtain erasure of your personal data, as well as the right to data portability and the right to request restriction of the processing. To exercise your rights, please contact the data Protection Officer: privacy(at)haliodx(dot)com.
If necessary, you can lodge a claim with the CNIL www.cnil.fr.

Fields marked with an asterisk (*) are required!